Patients
At Spruce, we are dedicated to finding new ways to treat rare endocrine disorders. Our team is focused on advancing the development of novel therapies that improve outcomes for people with classic congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS), and other rare endocrine disorders. We are led by seasoned life sciences professionals who have significant experience in developing and commercializing orphan drug therapies.
With tildacerfont, we aim to advance the treatment paradigm for classic CAH patients with a non-steroidal approach designed to offer improved disease control and reduced glucocorticoid steroid burden in patients.
We are currently conducting clinical trials evaluating tildacerfont for the treatment of adults and children with classic CAH.
Meet Spruce Bio Chief Medical Officer, Dr. Will Charlton as he discusses classic Congenital Adrenal Hyperplasia (CAH) and it’s effects on patients.
To learn more about the condition of classic Congenital Adrenal Hyperplasia (CAH), watch these videos with Spruce Bio Chief Medical Officer and Endocrinologist, Dr. Will Charlton as he discusses classic CAH and its effects on patients.
As an innovative late-stage company, our efforts are built around the needs of patients and their loved ones. We approach our work every day with the goal of improving health outcomes and easing the disease burden for patients with rare endocrine disorders.
We listen intently to what the patient community tells us about living with conditions such as CAH, and aim to address these needs in our development programs. We have adapted our clinical trial programs to ensure the utmost safety and flexibility for participants as well as caregivers.
To learn more about Spruce advocacy or to ask us a question, we invite patient and family caregiver advocates to connect with us at pel@nullsprucebio.com.
